Your browser doesn't support javascript.
loading
Prospective multicenter surveillance study of branch-duct intraductal papillary mucinous neoplasm of the pancreas; risk of dual carcinogenesis.
Ohtsuka, Takao; Maguchi, Hiroyuki; Tokunaga, Shoji; Hijioka, Susumu; Takayama, Yukiko; Koshita, Shinsuke; Hanada, Keiji; Sudo, Kentaro; Uehara, Hiroyuki; Tanno, Satoshi; Tada, Minoru; Kimura, Wataru; Nakamura, Masafumi; Kin, Toshifumi; Kamata, Ken; Masamune, Atsushi; Iwashita, Takuji; Akahoshi, Kazuya; Ueki, Toshiharu; Okamura, Keiya; Kato, Hironari; Kumagi, Teru; Kawabe, Ken; Yoshida, Koji; Mukai, Tsuyoshi; Sakagami, Junichi; Hirono, Seiko; Abue, Makoto; Nakafusa, Tomoki; Morita, Makiko; Shimosegawa, Toru; Tanaka, Masao.
  • Ohtsuka T; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Digestive Surgery, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan. Electronic address: takao-o@kufm.kagoshima-u.ac.jp.
  • Maguchi H; Education and Research Center, Teine-Keijinkai Hospital, Sapporo, Hokkaido, Japan. Electronic address: maguchi@tb3.so-net.ne.jp.
  • Tokunaga S; Medical Information Center, Kyushu University Hospital, Fukuoka, Japan.
  • Hijioka S; Department of Gastroenterology, Aichi Cancer Center Hospital, Nagoya, Aichi, Japan; Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Takayama Y; Department of Medicine, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan.
  • Koshita S; Department of Gastroenterology, Sendai City Medical Center, Sendai, Miyagi, Japan.
  • Hanada K; Department of Gastroenterology, Onomichi General Hospital, Onomichi, Japan.
  • Sudo K; Department of Gastroenterology, Chiba Cancer Center, Chiba, Japan.
  • Uehara H; Department of Hepatobiliary and Pancreatic Oncology, Osaka International Cancer Institute, Osaka, Japan.
  • Tanno S; Department of Gastroenterology, IMS Sapporo Digestive Center General Hospital, Sapporo, Hokkaido, Japan.
  • Tada M; Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan; Department of Gastroenterology, National Hospital Organization, Chiba Medical Center, Chiba, Japan.
  • Kimura W; First Department of Surgery, Graduate School of Medical Science, Yamagata University, Yamagata, Japan; Department of Surgery, Tokyo Metropolitan Kasukabe Hospital, Medical Corporation Zenjin-kai, Kasukabe, Saitama, Japan.
  • Nakamura M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Kin T; Center for Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Hokkaido, Japan.
  • Kamata K; Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Sayama, Osaka, Japan.
  • Masamune A; Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Iwashita T; First Department of Internal Medicine, Gifu University Hospital, Gifu, Japan.
  • Akahoshi K; Department of Gastroenterology, Aso Iizuka Hospital, Iizuka, Fukuoka, Japan.
  • Ueki T; Department of Gastroenterology, Fukuoka University Chikushi Hospital, Fukuoka, Japan.
  • Okamura K; Department of Bilio-pancreatolpgy, Sapporo Kosei General Hospital, Sapporo, Hokkaido, Japan.
  • Kato H; Department of Gastroenterology, Okayama University Hospital, Okayama, Japan.
  • Kumagi T; Department of Gastroenterology and Metabology, Ehime University Graduate School of Medicine, Toon, Ehime, Japan.
  • Kawabe K; Department of Gastroenterology, NHO Kyushu Medical Center, Fukuoka, Japan; Department of Gastroenterology, NHO Kokura Medical Center, Kitakyusu, Japan.
  • Yoshida K; Department of Gastroenterology and Hepatology, Kawasaki Medical School, Kurashiki, Okayama, Japan.
  • Mukai T; Department of Gastroenterology, Gifu Municipal Hospital, Gifu, Japan; Department of Gastroenterological Endoscopy, Kanazawa Medical University Hospital, Ishikawa, Japan.
  • Sakagami J; Department of Molecular Gastroenterology and Hepatology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan.
  • Hirono S; Second Department of Surgery, School of Medicine, Wakayama Medical University, Wakayama, Japan; Division of Hepato-Biliary-Pancreatic Surgery, Department of Gastroenterological Surgery, Hyogo Medical University, Hyogo, Japan.
  • Abue M; Department of Gastroenterology, Miyagi Cancer Center, Natori, Miyagi, Japan.
  • Nakafusa T; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Morita M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • Shimosegawa T; Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
  • Tanaka M; Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; Department of Surgery, Shimonoseki City Hospital, Shimonoseki, Yamaguchi, Japan. Electronic address: masaotan0601@gmail.com.
Pancreatology ; 2024 Aug 22.
Article en En | MEDLINE | ID: mdl-39191596
ABSTRACT

BACKGROUND:

The natural history of branch-duct intraductal papillary mucinous cystic neoplasms (BD-IPMNs) in the pancreas remains unclear. This study aimed to answer this clinical question by focusing on the development of concomitant pancreatic ductal adenocarcinomas (cPDAC).

METHODS:

The Japan Pancreas Society conducted a prospective multicenter surveillance study of BD-IPMN every six months for five years. The primary endpoints were progression of BD-IPMN, progression to high-grade dysplasia/invasive carcinoma (HGD/IC), and cPDAC. Factors predicting the progression of BD-IPMN to HGD/IC and development of cPDAC were also assessed as secondary endpoints.

RESULTS:

Among the 2104 non-operated patients, 348 (16.5 %) showed progression of primary BD-IPMN. Cumulative incidences of BD-IPMN with HGD/IC and cPDAC during the 5.17-year surveillance period were 1.90 % and 2.11 %, respectively, and standard incidence ratios of BD-IPMN with HGD/IC and cPDAC were 5.28 and 5.73, respectively. Of 38 cPDACs diagnosed during surveillance, 25 (65.8 %) were resectable. The significant predictive characteristics of BD-IPMN for progression to HGD/IC were larger cyst size (p = 0.03), larger main pancreatic duct size (p < 0.01), and mural nodules (p = 0.02). Significant predictive characteristics for the development of cPDAC were male sex (p = 0.03) and older age (p = 0.02), while the size of IPMN was not significant.

CONCLUSION:

Careful attention should be given to "dual carcinogenesis" during BD-IPMN surveillance, indicating the progression of BD-IPMN to HGD/IC and development of cPDAC distinct from BD-IPMN, although the establishment of risk factors that predict cPDAC development remains a challenge (UMIN000007349).
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Idioma: En Año: 2024 Tipo del documento: Article